Oligohydramnios is defined as decreased amniotic fluid volume (AFV) for gestational age. The volume of amniotic fluid changes over gestation, increasing linearly until 34 to 36 weeks gestation, at which point the AFV levels off (approximately 400mL) and remains constant until term.[1] The AFV then begins to decrease steadily after 40 weeks gestation, leading to reduced volume in post-term gestations. This pattern allows for clinical assessment of AFV throughout pregnancy using fundal height measurements and ultrasound evaluation.[2]
Amniotic fluid disorders should be included in the differential diagnosis whenever there is a discrepancy between the fundal height measurement and gestational age. Discrepancies should prompt an amniotic fluid assessment by ultrasound.
Transabdominal ultrasound evaluation of AFV includes the use of either the maximum vertical pocket (MVP) or the amniotic fluid index (AFI) depending on the institution. The sonographer systematically scans the abdomen and obtains an image that demonstrates the maximum vertical pocket - the deepest pocket of amniotic fluid that does not include fetal umbilical cord or body parts. The measurement should be made from the 12 o’clock position to the 6 o’clock position. The normal range for MVP is 2-8 cm: a pocket <2cm is considered oligohydramnios in both single and multifetal gestations[3][4] An MVP > 8 is considered polyhydramnios. The amniotic fluid index (AFI) is an alternative assessment of AFV. The AFI can be determined after 20 weeks of gestation by dividing the uterus into four quadrants through the umbilicus and determining the MVP in each quadrant. The sum of the four maximum vertical pockets is equal to the AFI. An AFI <5cm is consistent with oligohydramnios.[5]
The use of the maximum vertical pocket tends to overly diagnose cases of polyhydramnios, while the use of the AFI tends to underdiagnose cases of oligohydramnios. With this in mind, some institutions opt to use the MVP in gestations with low AFV and use the AFI in cases of high AFV. The MVP should serve to evaluate oligohydramnios in multifetal pregnancies, as you will not be able to measure all four quadrants for each fetus.[3][2]
The volume of amniotic fluid in the gestational sac is a result of a balance between fluid production and fluid movement out of the sac. In the first 20 weeks, lung secretions, along with hydrostatic and osmotic transport of maternal plasma through the fetal membranes, make up the majority of amniotic fluid production. At around week 16, the fetal kidneys begin to function, and the production of fetal urine steadily increases, taking over the majority of amniotic fluid production until the gestation is at term.[6]
Fetal genitourinary abnormalities can, therefore, result in a diagnosis of oligohydramnios after 16 to 20 weeks gestation. Examples include bladder outlet obstruction, dysplastic kidneys, and renal agenesis. Fetal swallowing and intramembranous absorption, thought to occur by osmotic absorption of fluid directly across the amnion and into fetal blood vessels, are the primary routes of amniotic resorption. Therefore, fetal gastrointestinal anomalies, such as tracheoesophageal fistula (incidence rate of approximately 1 in 3500 live births), can result in excess fluid volume, or polyhydramnios.[4]
Oligohydramnios complicates 4.4% of all pregnancies at term. The incidence of oligohydramnios is less than 1% in preterm pregnancies.[7]
Following ultrasound diagnosis by amniotic fluid assessment, clinical assessment should be focused on determining the etiology.
In addition to managing the underlying cause, prenatal management includes weekly maximum vertical pocket measurements and nonstress tests, which have demonstrated to decrease the occurrence of unexplained fetal death. Fetal growth should undergo serial assessment. Maternal hydration status also plays a vital role in management, particularly in cases of isolated oligohydramnios in the third trimester.[10]
Although there is some controversy surrounding the timing of delivery in cases of isolated oligohydramnios, the current recommendations support delivery at 37 weeks gestation, assuming membranes remain intact.[11]
Oligohydramnios is associated with many conditions/complications of pregnancy, and the differential breaks down into the following categories: maternal, fetal, placental, and idiopathic.[4]
The management and prognosis of oligohydramnios vary greatly depending on the underlying etiology, the gestational age at diagnosis, and the severity of oligohydramnios. Diagnosis of oligohydramnios during the second trimester is more likely to be associated with fetal or maternal anomalies, whereas diagnosis in the third trimester is more likely to be of unexplained origin. In one study, the etiology of oligohydramnios was unexplained in just 4% of second-trimester gestations, whereas 52% of those diagnosed in the third trimester were idiopathic. Only 10.2% of fetuses diagnosed in the second trimester survived, while the survival rate was 85.3% in those diagnosed in the third trimester.[12]
In cases of oligohydramnios diagnosed in the second trimester, pulmonary hypoplasia is the most significant predictor of fetal mortality. The mortality rate of second-trimester oligohydramnios can be as high as 90%, with pulmonary hypoplasia accounting for 87% of those deaths. The most severe pulmonary hypoplasia occurs with oligohydramnios before or during 16 to 24 weeks gestational age, when the terminal sacs of the fetal lung are developing. Low AFV during the second and early third trimester also increases the likelihood of limb contractures and birth defects due to compression of fetal parts.[12]
There are several additional complications to be aware of during the labor course of a gestation complicated by oligohydramnios. These include an increased risk of umbilical cord compression, meconium aspiration, cesarean delivery, fetal heart rate decelerations, and nonreactive fetal tracings.[1] Administration of 1 to 2 liters of oral or intravenous fluids during labor shown to transiently increase AFV and decrease cord compression over the labor course.[10]
Patient education regarding oligohydramnios should focus on the importance of receiving routine prenatal care throughout the course of pregnancy. Regular prenatal care allows the health care team to recognize and diagnose gestational complications, such as oligohydramnios. The clinical care team can then formulate an appropriate follow-up plan to minimize the risk of both the fetal and maternal complications associated with oligohydramnios.
The care and management of patients with amniotic fluid disorders rely on interprofessional communication among several providers to ensure adequate screening, diagnosis, and management of these conditions in the antepartum, partum, and postpartum periods. Obstetricians or clinically trained midwives often detect oligohydramnios during routine prenatal care visits.
Following diagnosis, it is often necessary to consult maternal-fetal medicine specialists and neonatologists who can help to develop an optimal care plan to limit the risk of complications for both the mother and the fetus. The care plans include antepartum management, the timing of delivery, and postpartum care that are each catered to the underlying etiology of oligohydramnios.[13]
[1] | Rabie N,Magann E,Steelman S,Ounpraseuth S, Oligohydramnios in complicated and uncomplicated pregnancy: a systematic review and meta-analysis. Ultrasound in obstetrics [PubMed PMID: 27062200] |
[2] | Magann EF,Bass JD,Chauhan SP,Young RA,Whitworth NS,Morrison JC, Amniotic fluid volume in normal singleton pregnancies. Obstetrics and gynecology. 1997 Oct; [PubMed PMID: 9380309] |
[3] | Ippolito DL,Bergstrom JE,Lutgendorf MA,Flood-Nichols SK,Magann EF, A systematic review of amniotic fluid assessments in twin pregnancies. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2014 Aug; [PubMed PMID: 25063400] |
[4] | Peipert JF,Donnenfeld AE, Oligohydramnios: a review. Obstetrical [PubMed PMID: 2067755] |
[5] | Hughes DS,Magann EF,Whittington JR,Wendel MP,Sandlin AT,Ounpraseuth ST, Accuracy of the Ultrasound Estimate of the Amniotic Fluid Volume (Amniotic Fluid Index and Single Deepest Pocket) to Identify Actual Low, Normal, and High Amniotic Fluid Volumes as Determined by Quantile Regression. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2020 Feb; [PubMed PMID: 31423632] |
[6] | Brace RA, Physiology of amniotic fluid volume regulation. Clinical obstetrics and gynecology. 1997 Jun; [PubMed PMID: 9199840] |
[7] | Hou L,Wang X,Hellerstein S,Zou L,Ruan Y,Zhang W, Delivery mode and perinatal outcomes after diagnosis of oligohydramnios at term in China. The journal of maternal-fetal [PubMed PMID: 30486718] |
[8] | Hesson A,Langen E, Outcomes in oligohydramnios: the role of etiology in predicting pulmonary morbidity/mortality. Journal of perinatal medicine. 2018 Oct 25; [PubMed PMID: 29924737] |
[9] | Clark SL,Sabey P,Jolley K, Nonstress testing with acoustic stimulation and amniotic fluid volume assessment: 5973 tests without unexpected fetal death. American journal of obstetrics and gynecology. 1989 Mar; [PubMed PMID: 2929695] |
[10] | Patrelli TS,Gizzo S,Cosmi E,Carpano MG,Di Gangi S,Pedrazzi G,Piantelli G,Modena AB, Maternal hydration therapy improves the quantity of amniotic fluid and the pregnancy outcome in third-trimester isolated oligohydramnios: a controlled randomized institutional trial. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2012 Feb; [PubMed PMID: 22298867] |
[11] | ACOG Committee Opinion No. 764: Medically Indicated Late-Preterm and Early-Term Deliveries. Obstetrics and gynecology. 2019 Feb; [PubMed PMID: 30681545] |
[12] | Shipp TD,Bromley B,Pauker S,Frigoletto FD Jr,Benacerraf BR, Outcome of singleton pregnancies with severe oligohydramnios in the second and third trimesters. Ultrasound in obstetrics [PubMed PMID: 8776235] |
[13] | Committee opinion no. 501: Maternal-fetal intervention and fetal care centers. Obstetrics and gynecology. 2011 Aug; [PubMed PMID: 21775875] |